Q1 2025 MedPlus Health Services Ltd Earnings Call Transcript
Key Points
- Medplus Health Services Ltd (BOM:543427) has expanded its network to 4,444 pharmacy outlets across 650 cities in 10 states.
- The company has seen a significant increase in private label sales, which now constitute 15.8% of total revenue.
- Revenue from pharmacy operations grew by 24% year-on-year on a GMV basis.
- Diagnostic segment revenue grew to INR242 million in Q1 FY25 compared to INR139 million in Q1 FY24.
- The company has a strong presence in Tier 2 cities and beyond, with 45% of its stores located in these areas.
- Q1 is typically a slow quarter for Medplus Health Services Ltd (BOM:543427), impacting overall performance.
- There were 29 store closures in Q1, resulting in a net addition of only 37 stores compared to 174 in Q4.
- The operating EBITDA margin for the quarter was relatively low at 2.9%.
- There was a significant marketing spend of INR95 million, which impacted profitability.
- Inventory provisioning and other adjustments negatively affected gross margins by approximately 0.5%.
Ladies and gentlemen, good day and welcome to the MedPlus Health Services Limited Q1 and FY25 earnings conference call. As a reminder, all participant lines will be in listen-only mode and there will be an opportunity for you to ask question after the presentation concludes. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Srinivas. Thank you and over to you, sir.
Thank you, (inaudible) Good evening, everyone. On behalf of MedPlus it's my atmost pleasure to welcome you all to the MedPlus Q1 FY25 earnings call to discuss the financial results of MedPlus for the first quarter of FY25, which were announced on August 2, 2024. We have with us today, the senior management team represented by Mr. Madhukar Reddy, Gangadi, CEO and MD; Mr. Sujit Mahato, CFO; and Mr. Chetan Dikshit, CSO.
Before we begin, I would like to mention that some of the statements made in today's discussion may be forward-looking in nature and may involve risks and uncertainties. Please
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
